遠大醫藥(00512.HK)創新產品治療COVID-19臨床試驗達主要終點
遠大醫藥(00512.HK)公布,澳洲全資附屬Grand Medical正在開發的用於重症領域的全球創新藥物STC3141,在中 國開展的用於治療急性呼吸窘迫綜合症Ib期臨床試驗已完成全部患者入組,臨床研究報告預計未來六個月內完成;在歐洲完成的用於治療重症新冠肺炎(COVID-19)IIa期臨床試驗亦成功達到主要臨床研究終點。
STC3141為集團自主開發的全新作用機制的全球創新小分子化合物,通過中和胞外游離組蛋白和中性粒細胞誘捕網來逆轉機體過度免疫反應造成的器官損傷,可用於多種重症適應症。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.